Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 11/20 | 0.61 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.53 |
| ▸ | PREP | P48147 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31473142 | 0.93 | ALDH1A1 (0.58) | ACEACE2PREPALDH1A1CYP3A4 | |
| SCHEMBL14673048 | 0.88 | ACE (0.63) | ACEACE2PREPLMNAALDH1A1 | |
| SCHEMBL14673049 | 0.88 | ACE (0.63) | ACEACE2PREPLMNAALDH1A1 | |
| SCHEMBL6243546 | 0.87 | ACE (0.66) | ACEACE2PREPLMNAALDH1A1 | |
| SCHEMBL6244068 | 0.87 | ACE (0.66) | ACEACE2PREPLMNAALDH1A1 | |
| SCHEMBL9477156 | 0.86 | ACE (0.76) | ACEACE2REN | |
| SCHEMBL5970431 | 0.86 | ACE (0.76) | ACEACE2REN | |
| SCHEMBL8268894 | 0.86 | ACE (0.76) | ACEACE2REN | |
| SCHEMBL9574253 | 0.86 | ACE (0.76) | ACEACE2REN | |
| SCHEMBL31197026 | 0.86 | ACE (0.67) | ACEACE2PREPLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008784-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICAL USE FOR THE TREATMENT OR PREVENTION OF VASCULAR DISEASES | VASTHERA CO LTD (KR) | 2026-01-08 | — | — | US | disclosed |
| EP-4547673-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICAL USE FOR THE TREATMENT OR PREVENTION OF VASCULAR DISEASES | VASTHERA Co. Ltd. (KR) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024005556-A1 | Compounds, pharmaceutical compositions containing them and their medical use for the treatment or prevention of vascular diseases | VASTHERA CO., LTD. (KR) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008784-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICAL USE FOR THE TREATMENT OR PREVENTION OF VASCULAR DISEASES | PRDX1, PRDX2, PRDX6 | ACE 2152/4885ACE2 1536/4885PREP 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.